MYC and therapy resistance in cancer: risks and opportunities
G Donati, B Amati - Molecular oncology, 2022 - Wiley Online Library
The MYC transcription factor, encoded by the c‐MYC proto‐oncogene, is activated by
growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways …
growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways …
[HTML][HTML] Ferroptosis in hematological malignancies and its potential network with abnormal tumor metabolism
J Zhang, Y Liu, Q Li, A Xu, Y Hu, C Sun - Biomedicine & Pharmacotherapy, 2022 - Elsevier
Ferroptosis, a new type of regulated cell death, displays characteristics that transparently
differ from apoptosis, autophagy and necroptosis. There is growing appreciation that …
differ from apoptosis, autophagy and necroptosis. There is growing appreciation that …
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance
The myeloma surface proteome (surfaceome) determines tumor interaction with the
microenvironment and serves as an emerging arena for therapeutic development. Here, we …
microenvironment and serves as an emerging arena for therapeutic development. Here, we …
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment
C Giallongo, I Dulcamare, D Tibullo, V Del Fabro… - Oncogenesis, 2022 - nature.com
Mesenchymal stromal cells (MSCs) within the protective microenvironment of multiple
myeloma (MM) promote tumor growth, confer chemoresistance and support metabolic needs …
myeloma (MM) promote tumor growth, confer chemoresistance and support metabolic needs …
Overcoming proteasome inhibitor resistance in the immunotherapy era
Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …
Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
The connections between metabolic state and therapy resistance in multiple myeloma (MM)
are poorly understood. We previously reported that electron transport chain (ETC) …
are poorly understood. We previously reported that electron transport chain (ETC) …
[HTML][HTML] The role of Extracellular Vesicles in glycolytic and lipid metabolic reprogramming of cancer cells: Consequences for drug resistance
B Polónia, CPR Xavier, J Kopecka, C Riganti… - Cytokine & Growth …, 2023 - Elsevier
In order to adapt to a higher proliferative rate and an increased demand for energy sources,
cancer cells rewire their metabolic pathways, a process currently recognized as a hallmark …
cancer cells rewire their metabolic pathways, a process currently recognized as a hallmark …
Multiple myeloma metabolism–a treasure trove of therapeutic targets?
Multiple myeloma is an incurable cancer of plasma cells that is predominantly located in the
bone marrow. Multiple myeloma cells are characterized by distinctive biological features that …
bone marrow. Multiple myeloma cells are characterized by distinctive biological features that …
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
AG Solimando, E Malerba, P Leone, M Prete… - Frontiers in …, 2022 - frontiersin.org
Multiple myeloma (MM) is still an incurable disease, despite considerable improvements in
treatment strategies, as resistance to most currently available agents is not uncommon. In …
treatment strategies, as resistance to most currently available agents is not uncommon. In …
The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma
Multiple myeloma (MM) is a hematological malignancy that emerges from antibody-
producing plasma B cells. Proteasome inhibitors, including the US Food and Drug …
producing plasma B cells. Proteasome inhibitors, including the US Food and Drug …